리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 05월
페이지 정보:영문 196 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 류마티스 치료학 시장은 2030년까지 607억 달러에 달할 전망
2023년에 489억 달러로 추정된 세계의 류마티스 치료학 시장은 2023-2030년의 분석 기간에 CAGR 3.1%로 성장하며, 2030년에는 607억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 질환 조절성 항 류마티스약(DMARDs)은 CAGR 3.1%를 기록하며, 분석 기간 종료시에는 513억 달러에 달할 것으로 예측됩니다. 비스테로이드성 항염증약(NSAIDs) 부문은 향후 7년간 CAGR이 3.6%로 예측됩니다.
미국 시장은 132억 달러, 중국은 CAGR 5%로 성장할 것으로 예측
미국의 류마티스 치료학 시장은 2023년에는 132억 달러에 달할 것으로 추정됩니다. 세계 2위의 경제대국인 중국은 2023-2030년의 분석 기간에 CAGR 5%로 추이하며, 2030년까지 120억 달러의 시장 규모에 달할 것으로 예측되고 있습니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 2023-2030년 각각 1.9%와 2.7%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 2.3%로 성장할 것으로 예측되고 있습니다. 호주, 인도, 한국 등의 국가가 촉진하는 아시아태평양의 시장은 2030년까지 76억 달러에 달할 것으로 예측됩니다.
2024년의 매력적인 신규 리포트 기능 소개
인플루언서 관여 통계에 대한 풀 액세스
디지털 아카이브와 "MarketGlass" 조사 플랫폼에 대한 무료 액세스. Global Industry Analysts, Inc.의 독자적인 MarketGlass 플랫폼은 전 세계 전문가의 창조성과 시장 지식을 통합적 및 협조적으로 활용할 수 있도록 지원합니다. Global Industry Analysts, Inc.의 최첨단 툴은 시장 참여 기업의 프라이버시와 ID를 보호하면서 세계 클래스의 시장 전망을 가져옵니다. 리포트내 수치, 통계, 시장에 관한 설명은 이 분야의 전문가 및 인플루언서에 의해 공유된 완전하게 큐레이트된 인사이트에 기반하고 있습니다.
실시간 데이터 시뮬레이터·툴 및 맞춤형 리포트 작성 기능을 갖춘 인터랙티브 앙케이트에 참가할 수 있습니다.
기업간 스마트한 의견교환을 위한 피어 협업·인터랙티브 플랫폼에 대한 풀 클라이언트 액세스
1년간 무료 리포트 업데이트
주요 기업의 세계 시장 점유율을 포함한 경쟁 커버리지
복수 지역에 걸친 기업 시장 입지 분석(호조/활발/니치/마이너)
전문가/인플루언서 인터뷰, 팟캐스트, 프레스 발표, 이벤트 기조 강연의 YouTube 비디오에 대한 액세스
2024년 세계 경제에 기대하는 것
금융긴축과 이에 따른 금리 상승에 의해 발생하는 지정학적, 경제적 불안정성이 2024년 격동의 상황을 야기할 것으로 생각됩니다. 중동에서의 적대 행위 및 더욱 더 빈발하는 기후 재해 등 몇개의 요인이 회복의 길에 계속 압력을 가할 것으로 생각됩니다. 이러한 리스크 가운데 디스인플레이션의 조짐과 고질적인 인플레이션에 대한 불안감 완화, 공급망 정상화, 에너지 비용의 변동성에도 불구하고 가격 조정 등 몇 가지 긍정적인 요소도 구체화되고 있습니다. 인도 및 미국을 비롯한 G21 국가의 선거는 자본 흐름 및 투자전략에 영향을 미칠 가능성이 있습니다. 인도가 세계 투자처로서 주목받는 한편, 미국을 기반으로 하는 하이테크 기업은 재능과 자본의 역동적인 에코시스템에 의해 지원되며 계속 우위를 유지할 것으로 생각됩니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 감속하고 있으나 안정적이며, 규제 환경도 정비되고 있는 것으로 인해 고성장 가능성을 요구하는 투자자에게 계속 매력적입니다. 유럽은 금융긴축정책과 경기후퇴 리스크와의 싸움이 계속되며, 영국은 전망이 가장 어렵고, 2024년 경기후퇴 리스크가 가장 높습니다. 중국은 정부지출과 개인소비의 개선에 의지한 성장이 기대되며 계속해서 와일드 카드로 남아 있습니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 과제를 둘 다 제공할 것으로 생각됩니다. 성장에 대한 촉매로서 변동성을 수용하는 것과 함께 투자 판단 결정에서 민첩성과 전략적 선견성이 생존을 위해 여전히 중요할 것입니다.
조사 대상 기업의 예(총 46건)
AbbVie, Inc.
Amgen, Inc.
Bristol-Myers Squibb Company
Genentech, Inc.
Janssen Biotech, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi SA
Takeda Pharmaceutical Co., Ltd.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장의 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Rheumatology Therapeutics Market to Reach $60.7 Billion by 2030
The global market for Rheumatology Therapeutics estimated at US$48.9 Billion in the year 2023, is expected to reach US$60.7 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Disease Modifying Anti-Rheumatic Drugs (DMARDs), one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$51.3 Billion by the end of the analysis period. Growth in the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is estimated at 3.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $13.2 Billion, While China is Forecast to Grow at 5% CAGR
The Rheumatology Therapeutics market in the U.S. is estimated at US$13.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12 Billion by the year 2030 trailing a CAGR of 5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 2.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.6 Billion by the year 2030.
Introducing Our Exciting New Report Features for 2024
Full access to influencer engagement stats
Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
Select Competitors (Total 46 Featured) -
AbbVie, Inc.
Amgen, Inc.
Bristol-Myers Squibb Company
Genentech, Inc.
Janssen Biotech, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi SA
Takeda Pharmaceutical Co., Ltd.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Rheumatology Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Rheumatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Uric Acid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Uric Acid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Uric Acid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for Psoriatic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 29: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 30: World 16-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 32: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 33: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 35: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 36: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 37: World Rheumatology Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 38: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 39: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: World 16-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Osteoarthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 42: World Historic Review for Osteoarthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: World 16-Year Perspective for Osteoarthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 45: World Historic Review for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: World 16-Year Perspective for Online by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 47: USA Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: USA Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: USA 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: USA Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: USA 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: USA Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: USA 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
CANADA
TABLE 56: Canada Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Canada 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Canada 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Canada 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
JAPAN
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 65: Japan Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Japan 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Japan 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Japan 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
CHINA
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 74: China Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: China Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: China 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: China Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: China 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: China Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: China 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
EUROPE
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 83: Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Rheumatology Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Europe 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Europe 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Europe 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
FRANCE
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 95: France Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: France Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: France 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: France Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: France 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 101: France Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: France Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: France 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
GERMANY
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 104: Germany Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Germany 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 107: Germany Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Germany 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 110: Germany Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Germany Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Germany 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
ITALY
TABLE 113: Italy Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Italy 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Italy 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 119: Italy Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Italy Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Italy 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
UNITED KINGDOM
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 122: UK Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: UK Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: UK 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 125: UK Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: UK Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: UK 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 128: UK Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: UK Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: UK 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
SPAIN
TABLE 131: Spain Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Spain Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Spain 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 134: Spain Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Spain Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Spain 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 137: Spain Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Spain Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Spain 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
RUSSIA
TABLE 140: Russia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Russia Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Russia 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 143: Russia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Russia Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Russia 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 146: Russia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Russia Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Russia 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Rest of Europe Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Rest of Europe 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Rest of Europe Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Rest of Europe 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Rest of Europe Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Rest of Europe 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Asia-Pacific Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 168: Asia-Pacific Historic Review for Rheumatology Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
AUSTRALIA
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 170: Australia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Australia Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Australia 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 173: Australia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Australia Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Australia 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 176: Australia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Australia Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Australia 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
INDIA
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 179: India Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: India Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: India 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 182: India Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: India Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: India 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 185: India Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: India Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: India 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 188: South Korea Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: South Korea Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: South Korea 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 191: South Korea Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: South Korea Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: South Korea 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 194: South Korea Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: South Korea Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: South Korea 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Rest of Asia-Pacific Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Rest of Asia-Pacific Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Asia-Pacific Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
LATIN AMERICA
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 206: Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Rheumatology Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Latin America 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 209: Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Latin America Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Latin America 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 212: Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Latin America Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Latin America 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 215: Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 216: Latin America Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 217: Latin America 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 218: Argentina Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 219: Argentina Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 220: Argentina 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 221: Argentina Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 222: Argentina Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 223: Argentina 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 224: Argentina Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 225: Argentina Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 226: Argentina 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
BRAZIL
TABLE 227: Brazil Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 228: Brazil Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 229: Brazil 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 230: Brazil Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 231: Brazil Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 232: Brazil 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 233: Brazil Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 234: Brazil Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 235: Brazil 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
MEXICO
TABLE 236: Mexico Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 237: Mexico Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 238: Mexico 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 239: Mexico Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 240: Mexico Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 241: Mexico 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 242: Mexico Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 243: Mexico Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 244: Mexico 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 246: Rest of Latin America Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 247: Rest of Latin America 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 249: Rest of Latin America Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 250: Rest of Latin America 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 252: Rest of Latin America Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 253: Rest of Latin America 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
MIDDLE EAST
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 254: Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Rheumatology Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 256: Middle East 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 257: Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 258: Middle East Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 259: Middle East 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 260: Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 261: Middle East Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 262: Middle East 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 263: Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 264: Middle East Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 265: Middle East 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
IRAN
TABLE 266: Iran Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 267: Iran Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 268: Iran 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 269: Iran Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 270: Iran Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 271: Iran 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 272: Iran Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 273: Iran Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 274: Iran 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
ISRAEL
TABLE 275: Israel Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 276: Israel Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 277: Israel 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 278: Israel Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 279: Israel Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 280: Israel 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 281: Israel Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 282: Israel Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 283: Israel 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 285: Saudi Arabia Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 286: Saudi Arabia 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 288: Saudi Arabia Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 289: Saudi Arabia 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 291: Saudi Arabia Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 292: Saudi Arabia 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 293: UAE Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 294: UAE Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 295: UAE 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 296: UAE Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 297: UAE Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 298: UAE 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 299: UAE Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 300: UAE Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 301: UAE 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 303: Rest of Middle East Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 304: Rest of Middle East 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 306: Rest of Middle East Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 307: Rest of Middle East 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 309: Rest of Middle East Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 310: Rest of Middle East 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
AFRICA
Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 311: Africa Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 312: Africa Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 313: Africa 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 314: Africa Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 315: Africa Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 316: Africa 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
TABLE 317: Africa Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 318: Africa Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 319: Africa 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030